Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Johnson and Johnson
Express Scripts
Medtronic
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR PRIMIDONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Primidone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006025 ↗ Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Completed National Cancer Institute (NCI) Phase 1 2001-01-05 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006025 ↗ Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Completed North American Brain Tumor Consortium Phase 1 2001-01-05 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006025 ↗ Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 2001-01-05 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.
NCT00006773 ↗ Bortezomib in Treating Patients With Recurrent Glioma Terminated National Cancer Institute (NCI) Phase 1 2001-05-01 Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Primidone

Condition Name

Condition Name for Primidone
Intervention Trials
Essential Tremor 5
Epilepsies, Partial 5
Seizures 5
Epilepsy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Primidone
Intervention Trials
Tremor 7
Essential Tremor 6
Epilepsy 5
Epilepsies, Partial 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Primidone

Trials by Country

Trials by Country for Primidone
Location Trials
United States 35
Hungary 2
France 1
Netherlands 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Primidone
Location Trials
North Carolina 4
Maryland 4
New York 3
Massachusetts 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Primidone

Clinical Trial Phase

Clinical Trial Phase for Primidone
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 12
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Primidone
Clinical Trial Phase Trials
Completed 16
Withdrawn 3
Terminated 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Primidone

Sponsor Name

Sponsor Name for Primidone
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 6
National Cancer Institute (NCI) 4
Duke University 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Primidone
Sponsor Trials
Other 21
Industry 16
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Baxter
Merck
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.